Overview
- Health Secretary Wes Streeting announced a trial of weight-loss drugs, in partnership with Eli Lilly, to address obesity and unemployment.
- The initiative is part of a £279 million investment in the UK life sciences sector to develop new treatments and assess their impact on work productivity.
- Critics argue that the plan oversimplifies the complex causes of unemployment and that weight-loss jabs alone cannot solve economic deprivation.
- The NHS is struggling to meet the high demand for these drugs, with warnings from healthcare professionals about overstretched resources.
- Public opinion is divided, with a YouGov poll showing more support among Labour voters for the rollout of weight-loss jabs to help the unemployed.